Introduction {#sec1}
============

Coronary artery disease (CAD), featured by narrowing or even occlusion of coronary arteries, is the primary cause of death and disability worldwide \[[@B1],[@B2]\]. Until now, the exact pathogenic mechanism of CAD remains unclear. Nevertheless, mounting evidence supports that genetic factors are crucial for its occurrence and development. In the first place, family aggregation of CAD was not uncommon, and past twin studies showed that the heredity grade of CHD was over 50% \[[@B3],[@B4]\]. In the second place, numerous genetic variants were found to be associated with an increased risk of CAD by previous genetic association studies, and screening of common causal variants was also shown to be a cost-efficient way to predict the individual risk of developing CAD \[[@B5],[@B6]\]. In summary, these findings jointly indicated that genetic predisposition to CAD played a central part in its pathogenesis.

Non-coding RNAs (ncRNAs) make up the vast majority of the human genome. Although ncRNAs do not encode proteins, it was evident that they play eminent roles in regulating expression levels of neighboring protein-encoding genes \[[@B7],[@B8]\]. Therefore, dysregulation of ncRNAs may cause abnormal gene expression and give rise to the development of multiple diseases. Antisense ncRNA in the INK4 locus (*ANRIL*) is located on human chromosome 9p21, a region that has been repeated found to be associated with atherosclerosis and its related ischemia cardiovascular diseases like CAD \[[@B9]\]. Although the exact function of *ANRIL* is still unknown, it was shown that the expression levels of several neighboring protein-encoding genes like cyclin-dependent kinase inhibitors 2A (*CDKN2A*), *CDKN2B*, and methylthioadenosine phosphorylase (*MTAP*) were modulated by *ANRIL* \[[@B10]\]. Previous investigations demonstrated that the abovementioned proteins were abundantly expressed in atherosclerotic lesions, and they could promote atherosclerosis by impacting vascular remodeling, thrombogenesis, and plaque stability \[[@B9],[@B10]\]. Hence, it is biologically plausible that these *ANRIL* polymorphisms may also be involved in atherosclerotic-related diseases like CAD. So far, some pilot studies already investigated potential correlations between *ANRIL* gene polymorphisms and the risk of CAD. But the results of these studies were controversial. Thus, we performed the present meta-analysis to better evaluate the roles of *ANRIL* polymorphisms in CAD.

Materials and methods {#sec2}
=====================

Literature search and inclusion criteria {#sec2-1}
----------------------------------------

This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@B11]\]. Potentially related literatures that were published before September 2018 were retrieved from PubMed, Medline, and Embase using the following combination of keywords: (*antisense noncoding RNA in the INK4 locus* OR *CDKN2B antisense RNA* OR *ANRIL* OR *CDKN2B-AS long non-coding RNA*) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (coronary heart disease OR coronary artery disease OR angina pectoris OR acute coronary syndrome OR myocardial infarction).

The references of retrieved articles were also screened to identify other potentially relevant studies.

To test the research hypothesis of this meta-analysis, included studies must meet all the following criteria: (i) case--control study on correlations between *ANRIL* polymorphisms and the risk of CAD; (ii) provide genotypic frequencies of investigated *ANRIL* polymorphisms in cases and controls; and (iii) full text in English available.

Studies were excluded if one of the following criteria was fulfilled: (i) not relevant to *ANRIL* polymorphisms and CAD; (ii) case reports or case series; and (iii) abstracts, reviews, comments, letters, and conference presentations.

For duplicate publications, we only included the study with the largest sample size for analyses.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

The following data were extracted from included studies: (i) name of the first author; (ii) publication time; (iii) country and ethnicity; (iv) sample size; and (v) genotypic distributions of *ANRIL* polymorphisms in cases and controls. Additionally, the probability value (*P*-value) of Hardy--Weinberg equilibrium (HWE) was also calculated. When necessary, we wrote to the corresponding authors for raw data. We used the Newcastle--Ottawa scale (NOS) to assess the quality of eligible studies \[[@B12]\]. This scale has a score range of 0--9, and studies with a score of more than 7 were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses {#sec2-3}
--------------------

All statistical analyses were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate strength of associations between *ANRIL* polymorphisms and the risk of CAD in all possible genetic models, and *P*-values ≤0.05 were considered to be statistically significant. Between-study heterogeneities were evaluated with *I^2^* statistic. If *I^2^* was greater than 50%, random-effect models (REMs) would be used to pool the data. Otherwise, fixed-effect models (FEMs) would be employed for synthetic analyses. Subgroup analyses by ethnicity of participants were subsequently performed. Sensitivity analyses were conducted to examine the stability of synthetic results. Funnel plots were used to assess publication bias.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

We found 105 potential relevant articles. Amongst these articles, a total of 15 eligible studies were finally included for synthetic analyses (see [Figure 1](#F1){ref-type="fig"}). The NOS score of eligible articles ranged from 7 to 8, which indicated that all included studies were of high quality. Baseline characteristics of included studies are shown in [Table 1](#T1){ref-type="table"}.

![Flowchart of study selection for the present study](bsr-39-bsr20181559-g1){#F1}

###### The characteristics of included studies for *ANRIL* polymorphisms and CAD

  First author, year    Country    Ethnicity    Type of disease   Sample size   Genotype distribution   *P*-value for HWE   NOS score   
  --------------------- ---------- ------------ ----------------- ------------- ----------------------- ------------------- ----------- ---
  **rs1333040**                                                                 TT/TC/CC                                                
  Kumar (2011)          India      West Asian   CAD               300/423       147/116/37              175/182/66          0.107       7
  Lin (2011)            Taiwan     East Asian   MI                411/1352      228/156/27              649/573/130         0.829       7
  Qi (2012)             China      East Asian   MI                142/192       91/44/7                 90/93/9             0.013       8
  Scheffold (2011)      Germany    Caucasian    MI                976/3532      292/503/181             889/1750/893        0.590       7
  Zhao (2016)           China      East Asian   CAD               456/683       236/184/36              336/293/54          0.370       7
  **rs1333049**                                                                 GG/GC/CC                                                
  Ahmed (2013)          Pakistan   West Asian   MI                294/290       65/166/63               87/180/23           \<0.001     8
  Çakmak (2015)         Turkey     Caucasian    CAD               220/240       54/120/46               85/115/40           0.917       7
  Haslacher (2016)      Austria    Caucasian    MI                493/431       139/236/118             112/222/97          0.514       7
  Lin (2011)            Taiwan     East Asian   MI                423/1361      100/218/105             395/655/311         0.213       7
  Qi (2012)             China      East Asian   MI                142/192       42/79/21                50/99/43            0.651       8
  Scheffold (2011)      Germany    Caucasian    MI                976/999       212/518/246             292/502/205         0.688       7
  Yang (2018)           China      East Asian   CAD               542/549       162/269/111             176/273/100         0.743       8
  **rs2383206**                                                                 AA/AG/GG                                                
  Abdullah (2008)       U.S.A.     Caucasian    CAD               310/560       56/124/130              143/279/138         0.934       8
  Kumar (2011)          India      West Asian   CAD               309/434       112/143/54              116/224/94          0.467       7
  Scheffold (2011)      Germany    Caucasian    MI                976/9053      183/521/272             2489/4583/1981      0.017       7
  Shendy (2017)         Egypt      West Asian   CAD               100/50        51/42/7                 23/15/12            0.009       8
  Zhou (2008)           China      East Asian   CAD               1360/1360     373/600/387             382/669/309         0.623       8
  **rs2383207**                                                                 GG/GA/AA                                                
  Abdullah (2008)       U.S.A.     Caucasian    CAD               310/560       139/121/50              147/277/136         0.807       8
  Çakmak (2015)         Turkey     Caucasian    CAD               220/240       83/101/36               102/118/20          0.079       7
  Chen (2009)           China      East Asian   CAD               212/232       107/69/36               71/114/47           0.920       8
  El-Menyar (2015)      Egypt      West Asian   CAD               236/152       146/77/12               84/58/10            0.998       7
  Kumar (2011)          India      West Asian   CAD               301/424       137/124/40              174/190/60          0.485       7
  Lin (2011)            Taiwan     East Asian   MI                415/1349      214/162/39              568/609/172         0.660       7
  Qi (2012)             China      East Asian   MI                142/192       78/55/9                 82/93/17            0.192       8
  Scheffold (2011)      Germany    Caucasian    MI                976/3532      183/519/274             1016/1770/746       0.628       7
  Yang (2018)           China      East Asian   CAD               540/548       247/236/57              244/251/53          0.317       8
  Zhou (2008)           China      East Asian   CAD               1360/1360     702/520/138             592/605/163         0.659       8
  **rs10757274**                                                                GG/GA/AA                                                
  Abdullah (2008)       U.S.A.     Caucasian    CAD               310/560       61/119/130              156/283/121         0.728       8
  El-Menyar (2015)      Egypt      West Asian   CAD               309/434       122/133/54              143/206/85          0.486       7
  Kumar (2011)          India      West Asian   CAD               310/439       116/135/59              144/210/85          0.591       7
  Mafi Golchin (2017)   Iran       West Asian   CAD               103/102       40/47/16                22/51/29            0.962       8
  Scheffold (2011)      Germany    Caucasian    MI                976/9053      208/515/253             2752/4543/1758      0.131       7
  Zhao (2016)           China      East Asian   CAD               291/385       82/137/72               130/188/67          0.945       7
  **rs10757278**                                                                GG/GA/AA                                                
  Abdullah (2008)       U.S.A.     Caucasian    CAD               310/560       59/135/116              159/294/107         0.162       8
  Chen (2009)           China      East Asian   CAD               212/232       107/69/36               71/114/47           0.920       8
  El-Menyar (2015)      Egypt      West Asian   CAD               309/427       89/142/78               103/214/110         0.957       7
  Scheffold (2011)      Germany    Caucasian    MI                976/718       211/522/243             224/366/128         0.308       7
  Shendy (2017)         Egypt      West Asian   CAD               100/50        37/45/18                13/18/19            0.057       8

*P*-values ≤0.05 were considered to be statistically significant. Abbreviation: MI, myocardial infarction.

Overall and subgroup analyses {#sec3-2}
-----------------------------

To investigate potential correlations between *ANRIL* polymorphisms and the risk of CAD, five studies about rs1333040 polymorphism, seven studies about rs1333049 polymorphism, five studies about rs2383206 polymorphism, ten studies about rs2383207 polymorphism, six studies about rs10757274 polymorphism, and five studies about rs10757278 polymorphism were enrolled for analyses.

Significant associations with the risk of CAD were detected for rs1333040 (dominant model: *P*\<0.0001, OR = 1.30, 95% CI: 1.17--1.44; recessive model: *P*\<0.0001, OR = 0.71, 95% CI: 0.62--0.82; allele model: *P*\<0.0001, OR = 1.25, 95% CI: 1.16--1.34), rs1333049 (dominant model: *P*=0.02, OR = 0.81, 95% CI: 0.67--0.96; allele model: *P*=0.02, OR = 0.86, 95% CI: 0.76--0.98), and rs2383207 (additive model: *P*=0.004, OR = 0.80, 95% CI: 0.69--0.93) polymorphisms in overall analyses.

Further subgroup analyses according to ethnicity of participants revealed that rs1333040 (dominant model and allele model), rs1333049 (recessive model), and rs2383207 (all genetic models) polymorphisms were significantly correlated with the risk of CAD in East Asians, rs2383206 (dominant model and allele model) and rs10757274 (dominant model and allele model) polymorphisms were significantly correlated with the risk of CAD in West Asians, while rs2383206 (dominant model, recessive model, and allele model), rs10757274 (dominant model, recessive model, and allele model) and rs10757278 (dominant model, recessive model, and allele model) polymorphisms were significantly correlated with the risk of CAD in Caucasians (see [Table 2](#T2){ref-type="table"}).

###### Overall and subgroup analyses for *ANRIL* polymorphisms and CAD

  Polymorphisms    Population   Sample size   Dominant comparison   Recessive comparison    Additive comparison   Allele comparison                                                             
  ---------------- ------------ ------------- --------------------- ----------------------- --------------------- ----------------------- -------------- ----------------------- -------------- -----------------------
  **rs1333040**    Overall      2285/6182     **\<0.0001**          **1.30 (1.17--1.44)**   **\<0.0001**          **0.71 (0.62--0.82)**   0.12           0.85 (0.69**--**1.04)   **\<0.0001**   **1.25 (1.16--1.34)**
                   East Asian   1009/2227     **0.03**              **1.37 (1.04--1.80)**   0.18                  0.82 (0.61**--**1.09)   0.06           0.76 (0.57**--**1.01)   **0.001**      **1.22 (1.08--1.38)**
  **rs1333049**    Overall      3090/4062     **0.02**              **0.81 (0.67--0.96)**   0.08                  1.24 (0.98**--**1.57)   0.35           1.05 (0.95**--**1.15)   **0.02**       **0.86 (0.76--0.98)**
                   Caucasian    1689/1670     0.37                  0.85 (0.60**--**1.20)   0.93                  1.02 (0.69**--**1.51)   0.32           1.10 (0.91**--**1.31)   0.59           0.93 (0.72**--**1.20)
                   East Asian   1107/2102     0.16                  0.82 (0.61**--**1.09)   **0.02**              **1.19 (1.03--1.38)**   0.31           1.07 (0.94**--**1.20)   0.06           0.87 (0.75**--**1.01)
  **rs2383206**    Overall      3055/11457    0.60                  0.91 (0.64**--**1.29)   0.33                  1.18 (0.84**--**1.65)   0.36           0.90 (0.72**--**1.13)   0.45           0.91 (0.72**--**1.16)
                   Caucasian    1286/9613     **\<0.0001**          **0.61 (0.53--0.71)**   **0.02**              **1.71 (1.08--2.71)**   0.61           0.88 (0.53**--**1.45)   **0.0002**     **0.68 (0.56--0.84)**
                   West Asian   409/484       **0.006**             **1.49 (1.12--1.99)**   0.19                  0.47 (0.15**--**1.46)   0.83           1.08 (0.53**--**2.19)   **0.002**      **1.36 (1.12--1.65)**
  **rs2383207**    Overall      4712/8589     0.09                  1.29 (0.96**--**1.72)   0.66                  0.94 (0.73**--**1.22)   **0.004**      **0.80 (0.69--0.93)**   0.15           1.17 (0.95**--**1.45)
                   Caucasian    1506/4332     0.97                  1.02 (0.42**--**2.47)   0.58                  1.21 (0.62**--**2.35)   0.48           0.88 (0.61**--**1.26)   0.94           0.98 (0.55**--**1.75)
                   East Asian   2669/3681     **0.0003**            **1.45 (1.18--1.79)**   **0.03**              **0.83 (0.71--0.98)**   **\<0.0001**   **0.77 (0.69--0.85)**   **0.0005**     **1.28 (1.11--1.48)**
                   West Asian   537/576       0.08                  1.24 (0.97**--**1.58)   0.57                  0.89 (0.61**--**1.32)   0.15           0.84 (0.65**--**1.07)   0.12           1.16 (0.96**--**1.39)
  **rs10757274**   Overall      2299/10973    0.89                  0.98 (0.69**--**1.39)   0.27                  1.23 (0.85**--**1.76)   0.15           0.86 (0.70**--**1.06)   0.89           0.98 (0.69**--**1.39)
                   Caucasian    1286/9613     **\<0.0001**          **0.62 (0.54--0.72)**   **0.03**              **1.92 (1.08--3.42)**   0.54           0.83 (0.46**--**1.50)   **0.001**      **0.65 (0.50--0.84)**
                   West Asian   722/975       **0.003**             **1.36 (1.11--1.67)**   0.17                  0.84 (0.66**--**1.08)   0.08           0.84 (0.69**--**1.02)   **0.04**       **1.28 (1.01--1.62)**
  **rs10757278**   Overall      1907/1987     0.81                  1.09 (0.63**--**1.87)   0.72                  1.10 (0.67**--**1.81)   0.24           0.83 (0.61**--**1.13)   0.87           1.03 (0.70**--**1.52)
                   Caucasian    1286/1278     **\<0.0001**          **0.60 (0.50--0.73)**   **0.008**             **1.95 (1.19--3.19)**   0.61           0.89 (0.57**--**1.39)   **\<0.0001**   **0.65 (0.52--0.81)**
                   West Asian   409/477       0.06                  1.33 (0.98**--**1.80)   0.35                  0.63 (0.24**--**1.66)   0.54           0.92 (0.70**--**1.20)   0.22           1.37 (0.83**--**2.27)

The values in bold represent that there are statistically significant differences between cases and controls. *P*-values ≤0.05 were considered to be statistically significant. Abbreviation: MI, myocardial infarction.

Sensitivity analyses {#sec3-3}
--------------------

We performed sensitivity analyses by excluding studies that deviated from HWE. No alterations of results were detected in sensitivity analyses, which suggested that our findings were statistically reliable.

Publication biases {#sec3-4}
------------------

Publication biases were evaluated with funnel plots. We did not find obvious asymmetry of funnel plots in any comparisons, which indicated that our findings were unlikely to be impacted by severe publication biases.

Discussion {#sec4}
==========

To the best of our knowledge, this is so far the most comprehensive meta-analysis on correlations between *ANRIL* polymorphisms and the risk of CAD. The overall analyses suggested that rs1333040, rs1333049, and rs2383207 polymorphisms were significantly associated with CAD risk in overall population. Further subgroup analyses revealed that rs1333040, rs1333049, and rs2383207 polymorphisms were significantly correlated with the risk of CAD in East Asians, rs2383206 and rs10757274 polymorphisms were significantly correlated with the risk of CAD in West Asians, while rs2383206, rs10757274, and rs10757278 polymorphisms were significantly correlated with the risk of CAD in Caucasians.

There are several points that need to be addressed about this meta-analysis. First, the exact function of *ANRIL* is still unclear, and therefore the underlying mechanisms of our positive findings need to be elucidated by future investigations. Second, the pathogenic mechanism of CAD is highly complex, and therefore it is unlikely that a single gene polymorphism can significantly contribute to its development. As a result, to better illustrate potential correlations of certain gene polymorphisms with CAD, we strongly recommend further studies to perform haplotype analyses and explore potential gene--gene interactions. Thirdly, according to a previous investigation, subjects carrying mutant allele of rs1333049 polymorphism had elevated TC, TG and LDL-C levels, and this may partially explain the observed significant correlation between this polymorphism and the risk of CAD. For other investigated polymorphisms, however, future studies are needed to investigate whether these polymorphisms are correlated with clinical and biochemical parameters of CAD \[[@B13]\].

As with all meta-analysis, the present study certainly has some limitations. First, our results were derived from unadjusted analyses, and lack of further adjusted analyses for age, gender, and co-morbidity conditions may impact the reliability of our findings \[[@B14]\]. Second, obvious heterogeneities were found in several subgroups, which indicated that the controversial results of included studies could not be fully explained by differences in ethnic background and type of disease, and other baseline characteristics of participants may also contribute to between-study heterogeneities \[[@B15]\]. Third, associations between *ANRIL* polymorphisms and CAD may also be modified by gene-gene and gene-environmental interactions. However, most eligible studies did not consider these potential interactions, which impeded us to perform relevant analyses accordingly \[[@B16]\]. On account of abovementioned limitations, our findings should be cautiously interpreted.

Conclusion {#sec5}
==========

In conclusion, our meta-analysis suggested that rs1333040, rs1333049, rs2383206, rs2383207, rs10757274, and rs10757278 polymorphisms might serve as genetic biomarkers of CAD in certain ethnicities. However, further well-designed studies are still warranted to confirm our findings.
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